Cynosure Advisors’s GSK GSK Stock Holding History

Cynosure Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-6,362	Closed	-$321K	–	93
2018 Q2	$321K	Buy	+6,362	New	+$320K	0.09%	179

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cynosure Advisors's GSK Position: Q3 2018 in Review

Cynosure Advisors sold out of GSK (GSK) in Q3 2018, closing a stake of 6,362 shares — an estimated $321K sold.

Cynosure Advisors first reported a position in GSK in Q2 2018 and held it in 1 quarter. The position peaked at $321K in Q2 2018. 787 funds tracked by Wall St. Rank hold GSK as of Q3 2018.

Cynosure Advisors reported no remaining GSK position as of Q3 2018 after selling out during the quarter.
Cynosure Advisors sold 6,362 GSK shares in Q3 2018, an estimated $321K.
Cynosure Advisors first reported a position in GSK in Q2 2018 and held it in 1 quarter.
Cynosure Advisors's GSK position peaked at $321K in Q2 2018.
787 funds tracked by Wall St. Rank held GSK as of Q3 2018.

Based on Cynosure Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.